In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies

Active Project Grant Awarded Last action

Award ID
R01AI167003
Recipient
Awarding agency
Obligated
$3,535,836

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 99% complete
Place of performance
La Jolla, CA 92037, USA

Award details come from USAspending.gov.

Description

Abstract
We have developed a novel gene therapeutic approach to achieve an HIV functional cure, wherein broadly neutralizing antibody (BNAB) genes are targeted to the endogenous heavy chain locus in B cells for expression as functional antigen-receptors (BCRS). This takes advantage of the precision of gene editing conferred by crispr-CAS9 reagents and homology-directed gene editing. We have shown that these broadly neutralizing BCRS respond to HIV ENV immunogens by signaling clonal expansion and germinal center maturation of the engineered cells and thereby generate durable, isotype-switched memory BNAB responses that could be deployed for long-term control of HIV. Given these features of B cell biology, which are preserved by our gene editing approach, we hypothesize that sufficient neutralizing antibody titers in serum could be generated from very few engineered B cells, including the levels achieved by in vivo delivery of genome-editing reagents directly to the target cells. In support of this approach, we have now shown that high-titer BNAB responses can be elicited in mice by vaccination with HIV-ENV immunogens when the animals are injected with a transcriptionally-targeted dual-AAV vector system carrying the BNAB editing reagents. Unlike injection of recombinant bnabs, or AAV- vectored delivery of BNAB-IGG expression cassettes to liver or muscle for long-term secretion from viral episomes, bnabs generated from in vivo gene-edited B cells in response to vaccination are expected to have the following advantages: 1) be boostable, as needed, in response to viral antigen, 2) express bnabs as all effector isotypes to expand antiviral immunity, 3) affinity-mature or evolve the BNAB response to keep-pace with a rapidly evolving virus, and 4) be better tolerated by the immune system. To further develop this approach, we have assembled a team that brings together expertise in B cell engineering, vector development, HIV vaccine design, and animal models to further develop this in vivo delivery approach to specifically and efficiently engineer B cells in vivo and to evaluate this approach as an in vivo HIV cure.

Transactions

Action Obligated Date
Amendment $145,896
Amendment $571,808
Amendment $700,174
Amendment $0
Amendment $73,362
Amendment $660,269
Amendment $738,581
Original award $645,746

Subawards

Subrecipient Amount Awarded
Tel Aviv University Awards a cost reimbursable subaward $145,896
University Of Southern California Award revised to reflect year 5 funding $203,177
University Of Southern California Yr4 funding $202,783
Tel Aviv University $138,331
University Of Southern California Yr3 funding $212,954
University Of Wisconsin System In Vivo Engineering of B cells for the secretion of HIV Broadly Neutralizing Antibodies $137,193
Tel Aviv University $143,196
University Of Southern California $213,807
Tel Aviv University Yr2 funding $143,196
Tel Aviv University Awards a cost reimbursable subaward $143,196
University Of Southern California $213,041
Show all 11

Quick answers

Who received award R01AI167003?

R01AI167003 was awarded to Scripps Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 2, 2021.

How much is award R01AI167003 worth?

$3,535,836 has been obligated on R01AI167003.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award